The homeobox gene MEIS1 is methylated in BRAFp.V600E mutated colon tumors

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Dihal, Ashwin A ^a   Boot, Arnoud ^a   Van Roon, Eddy H ^a   Schrumpf, Melanie ^a   Fariña Sarasqueta, Arantza ^a   Fiocco, Marta ^a   Zeestraten, Eliane C M ^a   Kuppen, Peter J K ^a   Morreau, Hans ^a   Van Wezel, Tom ^a   Boer, Judith M ^a,b,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c Netherlands Bioinformatics Center   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; VALINE;

AGED; ARTICLE; BRAF GENE; CANCER CELL; CANCER INHIBITION; CANCER PATIENT; CELL SELECTION; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; EPITHELIUM CELL; EXON; FEMALE; FROZEN SECTION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HOMEOBOX; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEIS1 GENE; MUTATIONAL ANALYSIS; PROMOTER REGION; STROMA; VALIDATION STUDY;

AGED; ASPARTIC ACID; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; VALINE;

EID: 84892381181     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079898     Document Type: Article

References (47)

1. Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1: 55-67. doi: 10.1038/35094067. PubMed: 11900252.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917. doi:10.1002/ijc.25516. PubMed: 21351269.
3. V600E in colorectal cancer by DNA methylation profiling. PLOS ONE 4: e8357. doi: 10.1371/journal.pone. 0008357. PubMed: 20027224.
4. Chang SC, Lin JK, Yang SH, Wang HS, Li AF et al. (2006) Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer 118: 1721-1727. doi:10.1002/ijc.21563. PubMed: 16231316.
5. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E et al. (2003) BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22: 9192-9196. doi:10.1038/sj.onc.1207061. PubMed: 14668801.
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954. doi:10.1038/nature00766. PubMed: 12068308.
7. Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT et al. (2012) Colorectal cancer: a tale of two sides or a continuum? Gut 61: 794-797. doi:10.1136/gutjnl-2012-302014. PubMed: 22490520.
8. Eklöf V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA et al. (2013) The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer 108: 2153-2163. doi:10.1038/bjc.2013.212. PubMed: 23660947.
9. Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY et al. (2012) Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value. Clin Cancer Res 18: 6531-6541. doi: 10.1158/1078-0432.CCR-12-0605. PubMed: 23045248.
10. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K et al. (2012) Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 18: 890-900. doi:10.1158/1078-0432.CCR-11-2246. PubMed: 22147942.
11. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA et al. (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58: 90-96. doi: 10.1136/gut.2008.155473. PubMed: 18832519.
12. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A (2010) Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 127: 367-380. PubMed: 19908233.
13. Phipps AI, Buchanan DD, Makar KW, Burnett-Hartman AN, Coghill AE et al. (2012) BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 21: 1792-1798. doi: 10.1158/1055-9965.EPI-12-0674. PubMed: 22899730.
14. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787-793. doi:10.1038/ng1834. PubMed: 16804544.
15. Curtin K, Slattery ML, Samowitz WS (2011) CpG Island Methylation in Colorectal Cancer: Past, Present and Future. Patholog Res Int 2011:902674. PubMed: 21559209
16. Ang PW, Loh M, Liem N, Lim PL, Grieu F et al. (2010) Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer 10: 227. doi:10.1186/1471-2407-10-227. PubMed: 20492682.
17. Shen L, Toyota M, Kondo Y, Lin E, Zhang L et al. (2007) Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 104: 18654-18659. doi: 10.1073/pnas.0704652104. PubMed: 18003927.
18. van Roon EH, Boot A, Dihal AA, Ernst RF, van Wezel T et al. (2013) BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer. Clin Epigenetics 5: 2. doi:10.1186/1868-7083-5-2.
19. Farina SA, Zeestraten EC, van Wezel T, van Lijnschoten G, van Eijk R et al. (2011) PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell Oncol (Dordr) 34: 523-531.
20. Dexter DL, Barbosa JA, Calabresi P (1979) N,N-dimethylformamide-induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res 39: 1020-1025. PubMed: 427742.
21. Fogh J, Wright WC, Loveless JD (1977) Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58: 209-214. PubMed: 833871.
22. Drewinko B, Romsdahl MM, Yang LY, Ahearn MJ, Trujillo JM (1976) Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res 36: 467-475. PubMed: 1260746.
23. Suardet L, Gaide AC, Calmès JM, Sordat B, Givel JC et al. (1992) Responsiveness of three newly established human colorectal cancer cell lines to transforming growth factors beta 1 and beta 2. Cancer Res 52: 3705-3712. PubMed: 1617643.
24. Brattain MG, Levine AE, Chakrabarty S, Yeoman LC, Willson JK et al. (1984) Heterogeneity of human colon carcinoma. Cancer Metastasis Rev 3: 177-191. doi:10.1007/BF00048384. PubMed: 6437669.
25. Leibovitz A, Stinson JC, McCombs WB III, McCoy CE, Mazur KC et al. (1976) Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36: 4562-4569. PubMed: 1000501.
26. Quinn LA, Moore GE, Morgan RT, Woods LK (1979) Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions. Cancer Res 39: 4914-4924. PubMed: 498117.
27. Murakami H, Masui H (1980) Hormonal control of human colon carcinoma cell growth in serum-free medium. Proc Natl Acad Sci U S A 77: 3464-3468. doi:10.1073/pnas.77.6.3464. PubMed: 6932031.
28. van Puijenbroek M, Dierssen JW, Stanssens P, van Eijk R, Cleton-Jansen AM et al. (2005) Mass spectrometry-based loss of heterozygosity analysis of single-nucleotide polymorphism loci in paraffin embedded tumors using the MassEXTEND assay: single-nucleotide polymorphism loss of heterozygosity analysis of the protein tyrosine phosphatase receptor type J in familial colorectal cancer. J Mol Diagn 7: 623-630. doi:10.1016/S1525-1578(10)60596-X. PubMed: 16258161.
29. Corver WE, Middeldorp A, ter Haar NT, Jordanova ES, van Puijenbroek M et al. (2008) Genome-wide Allelic State Analysis on Flow-Sorted Tumor Fractions Provides an Accurate Measure of Chromosomal Aberrations. Cancer Res 68: 10333-10340. doi: 10.1158/0008-5472.CAN-08-2665. PubMed: 19074902.
30. van Eijk R, Licht J, Schrumpf M, Talebian YM, Ruano D et al. (2011) Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-specific qPCR. PLOS ONE 6: e17791. doi:10.1371/journal.pone.0017791. PubMed: 21408138.
31. Xiong L, Catoire H, Dion P, Gaspar C, Lafrenière RG et al. (2009) MEIS1 intronic risk haplotype associated with restless legs syndrome affects its mRNA and protein expression levels. Hum Mol Genet 18: 1065-1074. doi:10.1093/hmg/ddn443. PubMed: 19126776.
32. van Wezel T, Lombaerts M, van Roon EH, Philippo K, Baelde HJ et al. (2005) Expression analysis of candidate breast tumour suppressor genes on chromosome 16q. Breast Cancer Res 7: R998-1004. doi: 10.1186/bcr1337. PubMed: 16280054.
33. Wettenhall JM, Smyth GK (2004) limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 20: 3705-3706. doi:10.1093/bioinformatics/bth449. PubMed: 15297296.
34. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article 3. PubMed: 16646809.
35. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing. J R Stat Soc B Stat Methodol 57: 289-300.
36. Crist RC, Roth JJ, Waldman SA, Buchberg AM (2011) A Conserved Tissue-Specific Homeodomain-Less Isoform of MEIS1 Is Downregulated in Colorectal Cancer. PLOS ONE 6: e23665. doi: 10.1371/journal.pone.0023665. PubMed: 21858198.
37. Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML (2007) Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev 21: 2762-2774. doi:10.1101/gad.1602107. PubMed: 17942707.
38. Serrano E, Lasa A, Perea G, Carnicer MJ, Brunet S et al. (2006) Acute Myeloid Leukemia Subgroups Identified by Pathway-Restricted Gene Expression Signatures. Acta Haematol 116: 77-89. doi: 10.1159/000093636. PubMed: 16914901.
39. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C et al. (2007) Transcriptome profile of human colorectal adenomas. Mol Cancer Res 5: 1263-1275. doi:10.1158/1541-7786.MCR-07-0267. PubMed: 18171984.
40. Lombaerts M, Middeldorp JW, van der Weide E, Philippo K, van Wezel T et al. (2004) Infiltrating leukocytes confound the detection of E-cadherin promoter methylation in tumors. Biochem Biophys Res Commun 319: 697-704. doi:10.1016/j.bbrc.2004.05.041. PubMed: 15178462.
41. Lilienbaum A, Legagneux V, Portier MM, Dellagi K, Paulin D (1986) Vimentin gene: expression in human lymphocytes and in Burkitt's lymphoma cells. EMBO J 5: 2809-2814. PubMed: 3792301.
42. Ji H, Ehrlich LI, Seita J, Murakami P, Doi A et al. (2010) Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 467: 338-342. doi:10.1038/nature09367. PubMed: 20720541.
43. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J et al. (2006) BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5: 2. PubMed: 16403224.
44. Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL et al. (2002) CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122: 1376-1387. doi: 10.1053/gast.2002.32997. PubMed: 11984524.
45. de Miranda NF, Hes FJ, van Wezel T, Morreau H (2012) Role of the microenvironment in the tumourigenesis of microsatellite unstable and MUTYH-associated polyposis colorectal cancers. Mutagenesis 27: 247-253. doi:10.1093/mutage/ger077. PubMed: 22294774.
46. Banerjea A, Ahmed S, Hands RE, Huang F, Han X et al. (2004) Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer 3: 21.
47. Jass JR, Do KA, Simms LA, Iino H, Wynter C et al. (1998) Morphology of sporadic colorectal cancer with DNA replication errors. Gut 42: 673-679. doi:10.1136/gut.42.5.673. PubMed: 9659163.